This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jacqueline, C.
Right arrow Articles by Potel, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jacqueline, C.
Right arrow Articles by Potel, G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2007, p. 3397-3400, Vol. 51, No. 9
0066-4804/07/$08.00+0     doi:10.1128/AAC.01242-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

In Vivo Efficacy of Ceftaroline (PPI-0903), a New Broad-Spectrum Cephalosporin, Compared with Linezolid and Vancomycin against Methicillin-Resistant and Vancomycin-Intermediate Staphylococcus aureus in a Rabbit Endocarditis Model{triangledown}

Cédric Jacqueline,1 Jocelyne Caillon,1* Virginie Le Mabecque,1 Anne-Françoise Miègeville,1 Antoine Hamel,1 Denis Bugnon,1 James Yigong Ge,2 and Gilles Potel1

Université de Nantes, Nantes Atlantique Universités, Thérapeutiques Cliniques et Expérimentales des Infections, EA3826, UFR Médecine, Nantes, France,1 Cerexa, Inc., Alameda, California2

Received 4 October 2006/ Returned for modification 28 January 2007/ Accepted 9 June 2007

Using the rabbit endocarditis model, we compared the activity of a new broad-spectrum cephalosporin, ceftaroline, with those of linezolid and vancomycin against methicillin-resistant Staphylococcus aureus. After a 4-day treatment, ceftaroline exhibited superior bactericidal in vivo activity against resistant S. aureus strains and appeared to be the most effective drug against a heterogeneous glycopeptide-intermediate S. aureus strain.

* Corresponding author. Mailing address: UPRES EA 3826, UER de Médecine, 1 rue Gaston Veil, 44035 Nantes, Cedex 01, France. Phone and fax: (33) 240-41-2854. E-mail: jocelyne.caillon{at}univ-nantes.fr

{triangledown} Published ahead of print on 25 June 2007.

Antimicrobial Agents and Chemotherapy, September 2007, p. 3397-3400, Vol. 51, No. 9
0066-4804/07/$08.00+0     doi:10.1128/AAC.01242-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Brown, S. D., Traczewski, M. M. (2009). In Vitro Antimicrobial Activity of a New Cephalosporin, Ceftaroline, and Determination of Quality Control Ranges for MIC Testing. Antimicrob. Agents Chemother. 53: 1271-1274 [Abstract] [Full Text]  
  • Sader, H. S., Fritsche, T. R., Jones, R. N. (2008). Antimicrobial Activities of Ceftaroline and ME1036 Tested against Clinical Strains of Community-Acquired Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 52: 1153-1155 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»